Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05235737 2023-08-31

PIRG

Phase 4 Unknown

36 enrolled

CNS

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma

NCT05915481 2023-06-23

SCARCE

Phase 1/2 Unknown

60 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Unknown

54 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05519202 2022-08-29

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Phase 2 Unknown

47 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04812002 2022-06-03

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Phase 2 Unknown

20 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Gestational Trophoblastic Disease

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Phase 2 Unknown

52 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT04886193 2021-05-13

FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis

Phase NA Unknown

20 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04589494 2021-01-14

Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain

Phase 2/3 Unknown

15 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Chronic Pain

NCT04530227 2020-11-13

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Phase 2 Unknown

30 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03545815 2020-08-10

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Phase 1 Unknown

10 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03917537 2019-04-25

WGA in Platinum-refractory HNSCC Underwent Nivolumab

Unknown

80 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Neoplastic Cells, Circulating

NCT03615313 2018-08-03

PAEMCMPAST

Phase 1/2 Unknown

50 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

Clinical Trials

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

PIRG

SCARCE

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

PD1 and PARP for Maintenance Therapy in NSLLC

FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis

Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

WGA in Platinum-refractory HNSCC Underwent Nivolumab

PAEMCMPAST